FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Aims to Modernize Inspection Program

[ Price : $8.95]

FDA undertakes a broad modernization of its inspection program, including expanded use of risk-based oversight, greater reliance o...

FDA Finalizes Updated Device Human Factors Guidance

[ Price : $8.95]

FDA issues an updated final guidance entitled Applying Human Factors and Usability Engineering to Medical Devices.

Lilly Gets Breakthrough Status for Pancreatic Cancer Therapy

[ Price : $8.95]

FDA grants Eli Lilly a breakthrough therapy designation for olomorasib as a monotherapy for treating adult patients with advanced ...

Sandoz to Pay $479 Million in Generic Drug Price-Fixing Litigation

[ Price : $8.95]

Sandoz reaches agreements totaling about $479 million to resolve most of its remaining exposure in long-running U.S. litigation al...

FDA Experts Back 'Operation Trialblazer' But Warn Agency Still Needs Stability

[ Price : $8.95]

FDA regulatory experts support the agency's new "Operation Trialblazer" initiative as an important step toward accelerating drug d...

FDA Cites Australian Drug Manufacturer for Quality System, Testing Deficiencies

[ Price : $8.95]

FDA cites Australian manufacturer Veganic SKN Limited for multiple current good manufacturing practice deficiencies following a 7/...

Draft Guidance on Biosimilar Container Closure Design

[ Price : $8.95]

A new FDA draft guidance outlines how sponsors should develop and evaluate container closure systems and device components used wi...

Commentary Questions FDA's Drug Innovation Policies

[ Price : $8.95]

A new Harvard Law School legal commentary argues that decades of policies designed to accelerate pharmaceutical innovation may hav...

Guidance on Adhesion Testing for Generic Transdermal/Topical Drugs

[ Price : $8.95]

FDA finalizes a guidance outlining how generic drug developers should evaluate the adhesion performance of transdermal and topical...

Ziltivekimab Misses Endpoint in Cardiovascular Outcomes Trial

[ Price : $8.95]

Novo Nordisk says its investigational anti-inflammatory drug ziltivekimab failed to reduce the risk of major adverse cardiovascula...